Biotech "Tweets of the Week" for February 16-20, 2015Too cold for catchy titles
|
|
#KentBrantly on #BobSimon's #60Minutes report talking about getting #Ebola & taking #ZMapp: I went from physician to patient to lab rat
— Donna Young (@ScripDonnaDC) February 16, 2015Awesome $blue related tweets today from
#BMTTandem15 regarding scd and bthal Ali F from bluebird presented
— Joshua B (@srqstockpicker) February 15, 2015@olddoggnewtrix @23aloha @robertcshea they could but since they can, should wait for 20$ Even higher if #stanford hits efficacy with RBC AEs
— Fabrice Bosom (@FBosom) February 16, 2015. @RyanBethencourt @LifeSciVC Lean works best w seasoned people who can think in integrative manner...so key Q: where do they get seasoned?
— Katrine Bosley (@ksbosley) February 16, 2015$REGN 402.40
Initiates at Outperform, PT $475 -Bernstein
— Tom Wrigley (@WrigleyTom) February 17, 2015$SRPT upgraded from Neutral to Buy at BofA/Merrill, PT $21
— Bio Stocks™ (@BioStocks) February 17, 2015What's the point of $NLNK PR'ing conference participation when nobody can actually listen to it?
— Brad Loncar (@bradloncar) February 17, 2015$CLTX miss in pediatric atopic dermatitis phase 2.
— PropThinker (@PropThinker) February 17, 2015CVS says PCSK9 drugs could cost $150B a year -- http://t.co/dVQVy6J4o3
— John Carroll (@JohnCFierce) February 17, 2015$EXEL breaking out the 200MA today & reaching the HoD $2.65 ..the next target is $2.86, but still have a gap @ $4.03 to fill !! Earning 2/24
— Joe (@GantosJ) February 17, 2015$ARWR institutional o: Orbimed exited and Baker Bros doubled down, is that right? I'll gamble the money I didn't spend on a January ski trip
— David Maizenberg (@biologypartners) February 18, 2015$RCPT !!!
— $$$ Money $$$ (@BiotechMoney18) February 17, 2015Sold 1/2 $cur 3.59 from 3.04 avg. Will see if day traders pick it up now over 3.60 to sell rest.
— Festo (@Festo50) February 17, 2015$VVUS OUT here at $2.8 for +12% on the technical bounce trade highlighted in the above tweet.
— TurboResearch (@TurboResearch) February 17, 2015Sold 1k shares of $aavl at 36.61
— Joshua B (@srqstockpicker) February 17, 2015BREAKING: Somewhere between 45-135 days ago a fund manager changed a position in a stock, but we don't know if there were offsetting hedges.
— Ivan the K™ (@IvanTheK) February 17, 2015JAMA viewpoint piece on @theranos' Stealth Research
http://t.co/RwgDUMlvL0
Totally agree w/ this highlighted point pic.twitter.com/47laJggIl0
— Andy Biotech (@AndyBiotech) February 18, 2015Reload year for $LLY and neuroscience Who better to fill the need $ACAD $ACAD $ACAD pic.twitter.com/MzJHlOK1vf
— dougheuring (@dougheuringaria) February 18, 2015let the $CLVS mania continue
— Juan P. Serrate, DVM (@JPZaragoza1) February 18, 2015Forget Actavis -- you can call the Big Pharma co. Allergan from now on -- $ACT
http://t.co/bRm9ggDYZg
— John Carroll (@JohnCFierce) February 18, 2015$ONCS $HBTX I-O combo therapy trial planned. I’m surprised we haven’t seen more similar PRs from other marginalized cancer drug stocks.
— Adam Feuerstein (@adamfeuerstein) February 18, 2015We've definitely hit a lull in weighty corporate news these last few weeks in biotech. Might have to start sleeping in if this keeps up.
— Brad Loncar (@bradloncar) February 18, 2015$SGEN files on AETHERA
— David Miller (@AlpineBV_Miller) February 18, 2015$CELG up 1.4% on U.S. front-line Revlimid approval; Wells Fargo notes "broad label, impressive updated OS benefits"
— Meg Tirrell (@megtirrell) February 18, 2015@bradloncar $ACAD been pretty green also since the Forbes mention
— dougheuring (@dougheuringaria) February 18, 2015@techwhitepapers @BioDueDiligence @bradloncar @sharkbiotech I don't think $GILD wants to change their style or thinks they need to.
— David Sobek (@dsobek) February 18, 2015This rumor is almost certainly false given that it's just market chatter, but the idea itself is not that bad IMO. $GILD $JUNO
— Brad Loncar (@bradloncar) February 18, 2015$ONCE initiated at Buy by Roth, PT $72
— Bio Stocks™ (@BioStocks) February 19, 2015$NBIX Prices 6.9M Share Offering at $36/share
— Bio Stocks™ (@BioStocks) February 19, 2015$vnda heloitz coming up short and they are guiding to a decrease in fanapt revenue yoy
— NathanAaron (@NathanAhron) February 19, 2015Wouldn't it make more sense to get an actual licence to KTE-C19 BEFORE leasing manufacturing plants? $KITE
— Jacob Plieth (@JacobPlieth) February 19, 2015Credit Suisse raised their $RCPT PT to $140 from $125 ahead of this weekend's UC presentation at ECCO.
— Brad Loncar (@bradloncar) February 19, 2015Not new, but still amazes me to see analysts like DB’s Alethia Young assume ZERO (!!) risk to ph3 asset. $ALNY pic.twitter.com/vJmQJAEYDi
— Adam Feuerstein (@adamfeuerstein) February 19, 2015LOL, $VNDA "will no longer report the number of HETLIOZ® prescriptions written". Don't want anyone to know how badly sales are going….
— biotechtoreador (@biotechtoreador) February 19, 2015$EXEL yet another example of "left for dead"/"most hated" stocks that rip 200% higher in a few months--recurring theme in small cap biotech
— Tony Pelz (@biotechtraderHB) February 19, 2015i'm almost done reading the $PCYC EPS release from yesterday
— zach (@zbiotech) February 19, 2015@ggl26 I'm also eyeballing that one
— Curtis (@biocurtis) February 19, 2015Anybody else find it shady that Aegis runs an offering the following day after $SGNL runs 229% and $CLRX runs 140%... Aegis is so scummy
— Shane Blackmon (@shaneblackmon) February 20, 2015@olddoggnewtrix @SudhanvaRaj I'm glad it's working. Jnap coverage pulled me in
— DeadCatBill (@getbillasap) February 19, 2015Continuing on, replace w/- $RCPT ECCO, $GWPH AAN, FDA LDT dx comms, $XLRN L/s data, $VRTX -661, selexipag, $AERI data, $BMRN -111, $CLDN IIb
— Vikram Khanna (@VikramKhanna_) February 19, 2015$EGRX keeps on rolling—now +90% in past 3 days. All this from the Trenda settlement with $Teva.
— Roy Friedman (@DewDiligence) February 19, 2015$XOMA HOD
— Bio Stocks™ (@BioStocks) February 19, 2015The life of an on-air biotech reporter: walking the halls of 30 Rock, muttering "carbapenem-resistant Enterobacteriaceae" over and over
— Meg Tirrell (@megtirrell) February 19, 2015This Nanosphere is now in the Stratosphere $NSPH
— S Manian (@DrSManian) February 19, 2015$IMMU spox tells me reported responses in today’s sac-gov data PR were partial responses. Term not used bc co. felt it was "too technical."
— Adam Feuerstein (@adamfeuerstein) February 19, 2015One interesting pt to $MNKD fans about $SNY's new CEO Olivier Brandicourt: he oversaw the failed Exubera launch during his tenure at $PFE ;)
— Andy Biotech (@AndyBiotech) February 20, 2015$CEMP @29ish chart is bullish and when it go over $30 it will be super bullish then after $32 it will be mega bullish. Got it? Ok
— $$$ Money $$$ (@BiotechMoney18) February 19, 2015@bradloncar the best line in that article:
"Proteonomix, which trades over the counter, closed Thursday unchanged at 1 cent."
— BioBounce.com (@BioBounce) February 19, 2015$ttph $cemp @OutFrontCNN just ran another report on antibiotic resistant "superbug"
— Joshua B (@srqstockpicker) February 20, 2015$JUNO closest to #VSB switch but $BLCM and $KITE not too far behind. Tech and bio acting very well, couldn't ask for better mkt leadership.
— CashRocket (@CashRocket) February 20, 2015@PharmDFoose Sold this $XOMA position at 3.89 today for an 8% gain. Not wanting to risk holding a position into their CC.
— Brice Foose (@PharmDFoose) February 20, 2015$ARIA - Sarrisa Capital confirms previous @megtirrell reporting: Nominating slate of directors, seeking ouster of CEO Harvey Berger
— Adam Feuerstein (@adamfeuerstein) February 20, 2015$MEIP Bank of America Initiates Coverage on MEI Pharma at Buy, Announces $9.00 PT
— BioBreakout (@BioBreakout) February 20, 2015MT @AndyBiotech $REGN 10-K: Two Phase I oncology assets REGN910 (anti-ANG2) & REGN421 (anti-DLL4) no longer in clinical development
— Laura Strong (@scientre) February 20, 2015